Clinical Trial

Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in Chinese adult participants with Acetylcholine receptor (AChR) + Generalized Myasthenia Gravis (gMG).
Protocol Amendment History 1 change
notable Trial sites expanded: 0 -> 10 locations 2026-06-23
Trial Details
NCT Number NCT07596784
Lead Sponsor Alexion Pharmaceuticals, Inc.
Conditions Generalized Myasthenia Gravis, gMG
Enrollment 20 participants
Start Date 2026-07-30
Primary Completion 2027-08-27 (estimated)
Study Completion 2027-08-27 (estimated)
Updated on ClinicalTrials.gov 2026-06-22